Menu Search
Equities

Medistim ASA

MEDIo:STO

Medistim ASA

Actions
  • Price (NOK)143.50
  • Today's Change0.00 / 0.00%
  • Shares traded747.00
  • 1 Year change-24.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NOKIncome statement in NOKView more

Year on year Medistim ASA had net income fall -8.90% from 113.97m to 103.82m despite a 7.00% increase in revenues from 491.94m to 526.36m. An increase in the selling, general and administrative costs as a percentage of sales from 31.31% to 32.37% was a component in the falling net income despite rising revenues.
Gross margin79.12%
Net profit margin18.58%
Operating margin23.30%
Return on assets21.05%
Return on equity25.95%
Return on investment25.53%
More ▼

Cash flow in NOKView more

In 2023, Medistim ASA did not generate a significant amount of cash. However, the company earned 113.19m from its operations for a Cash Flow Margin of 21.50%. In addition the company used 29.73m on investing activities and also paid 84.88m in financing cash flows.
Cash flow per share6.91
Price/Cash flow per share20.27
Book value per share22.12
Tangible book value per share19.13
More ▼

Balance sheet in NOKView more

Medistim ASA has little financial risk as the capital structure does not rely on leverage.
Current ratio4.82
Quick ratio2.75
Total debt/total equity0.0185
Total debt/total capital0.0181
More ▼

Growth rates in NOK

SmartText is unavailable
Div yield(5 year avg)1.47%
Div growth rate (5 year)14.87%
Payout ratio (TTM)80.78%
EPS growth(5 years)12.58
EPS (TTM) vs
TTM 1 year ago		-13.41
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.